We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Celerion Opens Operations in South Korea
News

Celerion Opens Operations in South Korea

Celerion Opens Operations in South Korea
News

Celerion Opens Operations in South Korea

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Celerion Opens Operations in South Korea "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Company's new Asian office is located within the Seoul National University Hospital Clinical Trials Center. 

Partnership with Seoul National University Hospital (SNUH) enables Celerion access to the 80-bed clinical research unit, particularly geared toward clinical pharmacology, oncology, and pediatrics, as well as the highly trained staff at this center. The new Asian office will be overseen by John Horkulak, Executive Director, Eurasian Site Operations. Mr. Horkulak brings over 20 years of experience in managing clinical pharmacology studies in patient populations to this role.

The focus of the SNUH Clinical Trials Center is translational medicine and aligns with Celerion’s strategic vision to provide effective global services that support growing interest in complex early clinical studies, often involving patients. In addition, Celerion has built relationships and audited three other clinical trial centers in South Korea to support the need for multi-site early clinical studies in patients often requiring confinement.

South Korea has become a leader in the Asia Pacific region for conducting clinical studies. Over the past 10 years, the South Korean government has provided funding and resources to create a network of well-equipped hospital-based clinical trial centers as a focus for training and growth in clinical pharmacology. By partnering with Celerion, SNUH and other clinical trial centers will gain exposure to our best practices and processes as well as broader involvement in global drug development. Through Celerion, clients will have access to patient populations suitable for participation in early clinical research in oncology, HCV, cardiovascular (atherosclerosis and hypertension), diabetes, arthritis, osteoporosis, pain, psychiatric conditions, Alzheimer's disease, Parkinson's disease, asthma and COPD. In addition, Celerion’s partners will provide expertise in pharmacogenetics and ethnic bridging studies in Asian populations.

“We are very pleased to have a presence in South Korea through our partnership with Seoul National University Hospital,” said Susan Thornton PhD., President and CEO at Celerion. “They are a highly respected institution and among the global leaders in the conduct of quality medical research. Collectively, we are in a solid position to successfully conduct and analyze complex clinical pharmacology studies involving patients with access to specialized equipment and facilities.”

“It is an honor for us to partner with Celerion, a global leader in early clinical research,” said Prof. Yung-Jue Bang MD PhD., President of the Biomedical Research Institute at SNUH, who also serves as the Director to the Clinical Trials Center. “The partnership enables us to participate more actively in global drug development programs as well as supporting the early clinical research needs for the emerging Korean drug discovery industry.”

Advertisement